|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A total of 482 patients with NSCLC who underwent ALK FISH analysis were evaluated for clinicopathological features, such as age, sex, smoking history, tumor stage, histological subtype, immunohistochemical profile, including ALK and EGFR mutation statuses, and survival.
|
31746406 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Analysis of plasma samples obtained post-progression on alectinib revealed that 26 of 49 (53%) samples harbored 16 distinct ALK mutations, with known alectinib-resistance mutations, I1171 T/N/S, G1202R, and V1180L, observed in 15 of 49 (31%) tumors.
|
31712133 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Familiarity with the unusual morphology and atypical FISH pattern is crucial given that this tumor has an activating ALK rearrangement and may benefit from targeted tyrosine kinase inhibitors in the future.
|
30741845 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Relationship between serum tumor markers and Anaplastic Lymphoma Kinase mutations in stage IV lung adenocarcinoma in Hubei province, Central China.
|
31489711 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The 8-week tumor volume decrease of >74% is significantly associated with longer OS in patients with ALK-rearranged NSCLC treated with crizotinib.
|
30985604 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In sum, we reveal for the first time the mechanism of cancer drug addiction in ALK-positive ALCL and the benefit of scheduled intermittent dosing in high-risk patient-derived tumors in vivo.
|
31804622 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This report describes the clinical course of a female former light smoker with metastatic lung adenocarcinoma whose tumor underwent histologic transformation from a well-differentiated lung adenocarcinoma to a well-differentiated lung squamous cell carcinoma in the same location at the left mainstem bronchus while maintaining the ALK fusion oncogene without any resistance mutations.
|
30959466 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All ALK immunoreactive tumors were confirmed to have ALK rearrangements by FISH with 1 tumor showing numerous (3 to 8) 3' ALK signals, an unusual FISH pattern not previously described in uterine IMTs.
|
29794871 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.
|
31540894 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ALK fusions and EGFR mutations conferred a significantly worse prognosis than did ERBB2 mutations and tumors that contained no mutations or fusions (P < 0.01).
|
31387567 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Baseline plasma and tumor tissue samples were collected from 198 patients with ALK-positive non-small-cell lung cancer from the registrational phase II study of lorlatinib.
|
30892989 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gilteritinib also binds to and inhibits the wild-type and mutated forms of ALK, resulting in reduced tumour cell proliferation in cancer cell types that overexpress the mutation.
|
30721452 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<i>ALK</i> positivity was significantly associated with younger age (P<0.001), solid predominant adenocarcinoma (P<0.001), variants of invasive adenocarcinoma (P<0.001), higher frequency of pleura invasion (P=0.040), smaller tumor size (P=0.014), mediastinal lymph node involvement (N2; P<0.001) and later pathologic stage (IIIA; P=0.001).
|
31737311 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sinonasal anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) without nodal involvement is extremely rare and the rarity of this tumor often leads to diagnostic dilemma.
|
30994389 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Liquid biopsy of CSF is more sensitive than liquid biopsy of plasma to detect targetable alterations, characterizing resistance mechanisms on progression and monitoring tumor response in patients with ALK-rearranged NSCLC with LM.
|
30659989 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using nucleophosmin-anaplastic lymphoma kinase-positive (NPM-ALK<sup>+</sup>) anaplastic large-cell lymphoma (ALCL) as model system, we found in cells and patient-derived tumor xenografts that STAT3 is constitutively acetylated as a result of ALK activity.
|
30692217 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ALK is a prognostic and predictive tumor marker in non-small cell lung carcinoma (NSCLC), and is more often found in lung adenocarcinomas.
|
31699471 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These findings indicate that HDAC inhibitor pretreatment followed by a new ALK inhibitor may be useful to circumvent resistance constituted by coexistence of resistance mutations and EMT in the heterogeneous tumor.
|
30737231 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ALK is a receptor tyrosine kinase, associated with many tumor types as diverse as anaplastic large cell lymphomas, inflammatory myofibroblastic tumors, breast and renal cell carcinomas, non-small cell lung cancer, neuroblastomas, and more.
|
30813562 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anaplastic lymphoma kinase (<i>ALK</i>)-rearranged non-small cell lung cancer (NSCLC) is an important molecular subgroup of tumors that are typically sensitive to tyrosine kinase inhibitors (TKIs).
|
31616196 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Diagnostic criteria, based on break-apart fluorescence in situ hybridization, were mirrored from ALK by analogy and include tumors with 5' deletions.
|
31447007 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that TFAP2B, ALK and a novel marker OLIG2 may serve as surrogate markers for PAX3/7-FOXO1 status what is especially beneficial in cases where poor quality tumour tissue is not suitable for reliable genetic analyses or shows inconclusive result.
|
31493794 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Methods</b>: ALK-positive NSCLC cells and various human ALK-negative cancer cells, especially human colorectal cancer (CRC) cells were used to examine the tumor suppression effect of brigatinib alone or in combination with autophagy inhibitors <i>in vitro</i> and <i>in vivo</i>.
|
31410188 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For example, the 5-year overall survival rate currently exceeds 25% among patients whose tumors have high PD-L1 expression (tumor proportion score of ≥50%) and 40% among patients with ALK-positive tumors.
|
31454018 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anaplastic lymphoma kinase (ALK) inhibitors are promising for ALK expressing tumors.
|
31119775 |
2019 |